Navigation Links
Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
Date:11/12/2012

IRVING, Texas, Nov. 12, 2012 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on enabling personalized healthcare through molecular profiling and blood-based diagnostic services, has added ROS1 and MGMT-Methylation to the company's evidence-based molecular profiling service. The company is one of only a few entities that offer both of these tests commercially. These markers are believed to serve as clinically-important aids in the development of treatment plans for patients with non-small cell lung cancer (NSCLC) and glioblastoma. 

Using fluorescence in situ hybridization (FISH) technology, Caris' tumor profiling service detects clinically-relevant rearrangements of the ROS1 gene, which are predominantly found in young, non-smoking lung cancer patients.  Patients with theses ROS1 rearrangements have shown increased positive responses to crizotinib, an oral ALK inhibitor. Caris has also added MGMT-methylation (MGMT-ME) gene testing for glioblastoma patients, using pyrosequencing to detect methylation levels. Pyrosequencing was shown to be the best predictor of overall survival and progression-free survival in glioblastoma patients¹. MGMT-ME status is believed to be a useful predictor of glioblastoma patient response to temozolomide, as well as offer helpful prognostic insights.

"The additions of these genes to our molecular profiling service further aid oncologists in determining the appropriate therapeutic regimen for their NSCLC and glioblastoma patients," said Sandeep Reddy, M.D., Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Senior Medical Director at Caris Life Sciences. "This demonstrates the dynamic, continually evolving nature of the service, which offers physicians the most clinically-relevant biomarker information available today." 

With more than 40,000 patients profiled to date, Caris Life Sciences' molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information. Oncologists are provided simple-to-read reports indicating which available chemotherapeutic, biologic and hormone therapies are potentially effective, along with those that are potentially less effective, as well as information on appropriate and enrolling clinical trials. This service presents the most clinically-relevant, patient-specific information doctors need to individualize cancer treatment.

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic, and theranostic services. The company's evidence-based molecular profiling service matches molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. This service uses the most advanced and clinically relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like molecular profiling and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.

¹Quillien, V., D. Figarella‐Branger, et al. (2012). "Comparative Assessment of 5 Methods (Methylation‐Specific Polymerase Chain Reaction, MethyLight, Pyrosequencing, Methylation‐Sensitive High‐Resolution Melting, and Immunohistochemistry) to Analyze O6‐Methylguanine‐DNAMethyltranferase in a Series of 100 Glioblastoma Patients." Cancer 118: 4201‐11.


'/>"/>
SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Garage Start-ups Now Possible in Life Sciences Industry
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. DiaTech Life Sciences Announces Medical Advisory Board
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
11. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... The Pittcon ... Pittcon 2019. Chuck has been a volunteer member of Committee since 1987. Since ... the board of directors and treasurer and was chairman for both the program and ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  ... Director and one of the founding commercial leaders responsible for the commercialization of ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. ... Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from the ... the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy Ph.D. ...
(Date:4/26/2016)... (PRWEB) , ... April 27, 2016 , ... ... of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual ... and international electrical, mechanical and electromechanical patent applications. He has an electrical engineering ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):